07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Immune Pharmaceuticals deal

Immune will spin out a new company focused on pain and neurology. The newco will own IP for AmiKet and other pain and neurology assets. Healthcare investor Novel Pain Therapeutics LLC (New York, N.Y.) will...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Hebrew University of Jerusalem, Immune Pharmaceuticals deal

Yissum, the tech transfer arm of the university, granted Immune exclusive, worldwide rights to patents covering a topical nano-formulated version of AmiKet to treat neuropathic pain. Yissum is eligible to receive up to $4.5 million...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

EpiCept, Immune Pharmaceuticals deal

The companies announced they will merge in a stock deal. After the deal, which is expected to close next quarter, former EpiCept shareholders will own 22.5% of the combined company, which will be named Immune...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

EpiCept, Meda sales and marketing update

EpiCept made several moves to save cash and extend its projected operations into 4Q12. EpiCept will receive $2.6 million in cash from Meda in exchange for relinquishing future milestones and royalties under a 2010 deal...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

AmiKet regulatory update

EpiCept said EMA's CHMP issued formal scientific advice on the development of AmiKet to treat chemotherapy-induced peripheral neuropathic pain (CIPN). CHMP recommended EpiCept include in an MAA a single, 12-week, 4-arm, factorial-designed trial in CIPN...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

AmiKet regulatory update

FDA granted Fast Track designation for EpiCept's AmiKet to treat neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with taxane-based chemotherapy. EpiCept plans to begin a Phase III trial of AmiKet...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

EpiCept neurology news

EpiCept engaged SunTrust Robinson Humphrey to advise on maximizing the commercial value of AmiKet , a topical cream containing amitriptyline and ketamine. EpiCept said it is in partnering discussions for AmiKet and plans to begin...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

EpiCept NP-1: Additional Phase IIb data

A double-blind, U.S. Phase IIb trial in >460 patients with painful CPN for at least 28 days following chemotherapy showed that twice-daily 4 mL topical EpiCept NP-1 for 6 weeks met the primary endpoint of...
08:00 , Feb 14, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Gilead Sciences Inc. (NASDAQ:GILD) lost $0.40 to $38.39 last week after resubmitting an NDA to FDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection. Last month, the agency refused to...
00:54 , Feb 8, 2011 |  BC Extra  |  Clinical News

EpiCept gains on EpiCept-NP1 data

EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT) gained $0.10 (13%) to $0.85 on Monday after the company said EpiCept NP-1 met the primary endpoint in a Phase IIb trial to treat chemotherapy-induced peripheral neuropathy (CPN). The topical cream...